{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T18:14:37Z","timestamp":1789496077560,"version":"build-2803163510"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:00:00Z","timestamp":1758153600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Biogen Italia"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40273-025-01539-3","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T15:44:43Z","timestamp":1758210283000},"page":"1463-1477","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments in Patients with Relapsing\u2013Remitting Multiple Sclerosis"],"prefix":"10.1007","volume":"43","author":[{"given":"Luca","family":"Prosperini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo Brescia","family":"Brescia Morra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9609-9556","authenticated-orcid":false,"given":"Carla","family":"Fornari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Perini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Bergamaschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Angelo","family":"Cortesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,18]]},"reference":[{"key":"1539_CR1","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1001\/jama.2020.26858","volume":"325","author":"MP McGinley","year":"2021","unstructured":"McGinley MP, Goldschmidt CH, Rae-Grant AD. Diagnosis and treatment of multiple sclerosis: a review. JAMA. 2021;325:765\u201379. https:\/\/doi.org\/10.1001\/jama.2020.26858.","journal-title":"JAMA"},{"issue":"2_suppl","key":"1539_CR2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1352458517708176","volume":"23","author":"M Battaglia","year":"2017","unstructured":"Battaglia M, Kobelt G, Ponzio M, Berg J, Capsa D, Dal\u00e9n J, et al. New insights into the burden and costs of multiple sclerosis in Europe: results for Italy. Mult Scler. 2017;23(2_suppl):104\u201311613. https:\/\/doi.org\/10.1177\/1352458517708176.","journal-title":"Mult Scler"},{"key":"1539_CR3","doi-asserted-by":"publisher","DOI":"10.7175\/fe.v21i1.1476","author":"PA Cortesi","year":"2020","unstructured":"Cortesi PA, Cozzolino P, Capra R, Cesana G, Mantovani LG. The economic burden of different multiple sclerosis courses: analysis from Italian administrative and clinical databases. Farmeconomia Health Econ Thera Pathways. 2020. https:\/\/doi.org\/10.7175\/fe.v21i1.1476.","journal-title":"Farmeconomia Health Econ Thera Pathways"},{"key":"1539_CR4","unstructured":"Official Journal of the European Union, C 176, 28 July 2006. https:\/\/eur-lex.europa.eu\/legal-content\/EN\/TXT\/?uri=OJ:C:2006:176:TOC. Accessed 18 July 2025."},{"issue":"15","key":"1539_CR5","doi-asserted-by":"publisher","first-page":"e1452","DOI":"10.1212\/wnl.0000000000008243","volume":"93","author":"LZ Ryerson","year":"2019","unstructured":"Ryerson LZ, Foley J, Chang I, Kister I, Cutter G, Metzger RR, et al. Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing. Neurology. 2019;93(15):e1452\u201362. https:\/\/doi.org\/10.1212\/wnl.0000000000008243.","journal-title":"Neurology"},{"issue":"2","key":"1539_CR6","doi-asserted-by":"publisher","first-page":"S523","DOI":"10.1016\/j.jval.2020.08.698","volume":"23","author":"P Cozzolino","year":"2020","unstructured":"Cozzolino P, Cortesi PA, Capra R, Patti F, Santoni L, Masera S, et al. PDG15 evolution of natalizumab use in two Italian multiple sclerosis centers. Value Health. 2020;23(2):S523. https:\/\/doi.org\/10.1016\/j.jval.2020.08.698.","journal-title":"Value Health."},{"issue":"3","key":"1539_CR7","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2217\/nmt-2021-0038","volume":"12","author":"M Moccia","year":"2022","unstructured":"Moccia M, Loperto I, Santoni L, Masera S, Affinito G, Carotenuto A, et al. Healthcare resource utilization and costs for extended interval dosing of natalizumab in multiple sclerosis. Neurodegener Dis Manag. 2022;12(3):109\u201316. https:\/\/doi.org\/10.2217\/nmt-2021-0038.","journal-title":"Neurodegener Dis Manag"},{"issue":"7","key":"1539_CR8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/s1474-4422(22)00143-0","volume":"21","author":"JF Foley","year":"2022","unstructured":"Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing\u2013remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022;21(7):608\u201319. https:\/\/doi.org\/10.1016\/s1474-4422(22)00143-0.","journal-title":"Lancet Neurol"},{"issue":"1","key":"1539_CR9","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1007\/s00415-023-11955-0","volume":"271","author":"M Filippi","year":"2024","unstructured":"Filippi M, Grimaldi L, Conte A, Totaro R, Valente MR, Malucchi S, et al. Intravenous or subcutaneous natalizumab in patients with relapsing\u2013remitting multiple sclerosis: investigation on efficiency and savings-the EASIER study. J Neurol. 2024;271(1):340\u201354. https:\/\/doi.org\/10.1007\/s00415-023-11955-0.","journal-title":"J Neurol"},{"issue":"12","key":"1539_CR10","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.amjmed.2020.05.049","volume":"133","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133(12):1380-1390.e2. https:\/\/doi.org\/10.1016\/j.amjmed.2020.05.049.","journal-title":"Am J Med"},{"issue":"14","key":"1539_CR11","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1177\/13524585211003020","volume":"27","author":"M Trojano","year":"2021","unstructured":"Trojano M, Rami\u00f3-Torrent\u00e0 L, Grimaldi LM, Lubetzki C, Schippling S, Evans KC, et al. A randomized study of natalizumab dosing regimens for relapsing\u2013remitting multiple sclerosis. Mult Scler. 2021;27(14):2240\u201353. https:\/\/doi.org\/10.1177\/13524585211003020.","journal-title":"Mult Scler"},{"key":"1539_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2024.105852","volume":"91","author":"A Mariottini","year":"2024","unstructured":"Mariottini A, Mealli F, Mattei A, Massacesi L. Comparative efficacy of subcutaneous versus intravenous natalizumab on annualized relapse rate: a post-hoc analysis of the REFINE study. Mult Scler Relat Disord. 2024;91:105852. https:\/\/doi.org\/10.1016\/j.msard.2024.105852.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"1539_CR13","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1007\/s40120-024-00647-0","volume":"13","author":"H Wiendl","year":"2024","unstructured":"Wiendl H, Foley J, Defer G, Zhovtis Ryerson L, Cohen JA, Arnold DL, et al. Patient preference for subcutaneous versus intravenous administration with every-6-week natalizumab (Tysabri\u00ae) dosing: NOVA phase IIIb extension study (part 2). Neurol Ther. 2024;13(5):1385\u2013401. https:\/\/doi.org\/10.1007\/s40120-024-00647-0.","journal-title":"Neurol Ther"},{"key":"1539_CR14","doi-asserted-by":"publisher","unstructured":"Ned H, Edwards RT. Cost\u2013consequence analysis of public health interventions. In: Edwards RT, McIntosh E, editors. Applied health economics for public health practice and research, handbooks in health economic evaluation. Oxford: Oxford Academic; 2019. https:\/\/doi.org\/10.1093\/med\/9780198737483.003.0010. (online edn).","DOI":"10.1093\/med\/9780198737483.003.0010"},{"key":"1539_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40120-021-00264-1","volume":"10","author":"A Wiyani","year":"2021","unstructured":"Wiyani A, Badgujar L, Khurana V, Adlard N. How have economic evaluations in relapsing multiple sclerosis evolved over time? A systematic literature review. Neurol Ther. 2021;10:557\u201383. https:\/\/doi.org\/10.1007\/s40120-021-00264-1.","journal-title":"Neurol Ther"},{"key":"1539_CR16","unstructured":"Cost consequence analysis: health economic studies. https:\/\/www.gov.uk\/guidance\/cost-consequence-analysis-health-economic-studies. Accessed 26 Apr 2025."},{"key":"1539_CR17","unstructured":"National Institute for Health and Care Excellence. NICE glossary. London: NICE. https:\/\/www.nice.org.uk\/Glossary?letter=C. Accessed 15 Apr 2025."},{"key":"1539_CR18","volume-title":"Methods for the economic evaluation of health care programmes","author":"MF Drummond","year":"2015","unstructured":"Drummond MF, Sculpher MJ, Torrance GW, O\u2019Brien BJ, Stoddart GL. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2015."},{"key":"1539_CR19","volume-title":"Measuring and valuing health benefits for economic evaluation","author":"J Brazier","year":"2007","unstructured":"Brazier J, Ratcliffe J, Salomon J, Tsuchiya A. Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press; 2007."},{"issue":"2","key":"1539_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12723-4","volume":"272","author":"H Inojosa","year":"2025","unstructured":"Inojosa H, Schriefer D, Ness NH, Dillenseger A, Akg\u00fcn K, Ziemssen T. Cost-consequence analysis of early vs. delayed natalizumab use in highly active relapsing\u2013remitting multiple sclerosis: a simulation study. J Neurol. 2025;272(2):153. https:\/\/doi.org\/10.1007\/s00415-024-12723-4.","journal-title":"J Neurol"},{"issue":"9","key":"1539_CR21","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0175","volume":"12","author":"V Bhan","year":"2023","unstructured":"Bhan V, Clift F, Baharnoori M, Thomas K, Patel BP, Blanchette F, et al. Cost-consequence analysis of ofatumumab for the treatment of relapsing\u2013remitting multiple sclerosis in Canada. J Comp Eff Res. 2023;12(9):e220175. https:\/\/doi.org\/10.57264\/cer-2022-0175.","journal-title":"J Comp Eff Res."},{"issue":"1","key":"1539_CR22","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/s1474-4422(11)70262-9","volume":"11","author":"G Comi","year":"2012","unstructured":"Comi G, De Stefano N, Freedman MS, Barkhof F, Polman CH, Uitdehaag BM, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol. 2012;11(1):33\u201341. https:\/\/doi.org\/10.1016\/s1474-4422(11)70262-9.","journal-title":"Lancet Neurol"},{"issue":"8","key":"1539_CR23","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1212\/wnl.5.8.580","volume":"5","author":"JF Kurtzke","year":"1955","unstructured":"Kurtzke JF. A new scale for evaluating disability in multiple sclerosis. Neurology. 1955;5(8):580\u20133. https:\/\/doi.org\/10.1212\/wnl.5.8.580.","journal-title":"Neurology"},{"issue":"9","key":"1539_CR24","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/nejmoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910. https:\/\/doi.org\/10.1056\/nejmoa044397.","journal-title":"N Engl J Med"},{"key":"1539_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.breast.2023.08.005","volume":"71","author":"A Zambelli","year":"2023","unstructured":"Zambelli A, Cazzaniga M, La Verde N, Munzone E, Antonazzo IC, Mantovani LG, et al. A cost-consequence analysis of adding pertuzumab to the neoadjuvant combination therapy in HER2-positive high-risk early breast cancer in Italy. Breast. 2023;71:113\u201321. https:\/\/doi.org\/10.1016\/j.breast.2023.08.005.","journal-title":"Breast"},{"key":"1539_CR26","unstructured":"Linee Guida AIFA per la compilazione del Dossier a supporto della domanda di rimborsabilit\u00e0 e prezzo di un medicinale 2020 (vs0.1). https:\/\/www.aifa.gov.it\/documents\/20142\/1307543\/2021.01.22_estratto_linee_guida_sezione_E.pdf. Accessed 28\/07\/2025."},{"key":"1539_CR27","first-page":"5","volume":"14","author":"F Fiorentino","year":"2021","unstructured":"Fiorentino F, Urbinati D. First Italian guidelines for the economic evaluation of health technologies: how do they compare to NICE standards? GIHTAD. 2021;14:5.","journal-title":"GIHTAD"},{"issue":"1","key":"1539_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2013-004073","volume":"4","author":"J Palace","year":"2014","unstructured":"Palace J, Bregenzer T, Tremlett H, Oger J, Zhu F, Boggild M, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open. 2014;4(1):e004073. https:\/\/doi.org\/10.1136\/bmjopen-2013-004073.","journal-title":"BMJ Open"},{"issue":"6","key":"1539_CR29","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1056\/nejmoa1917246","volume":"383","author":"SL Hauser","year":"2020","unstructured":"Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, et al. Ofatumumab versus teriflunomide in multiple sclerosis. N Engl J Med. 2020;383(6):546\u201357. https:\/\/doi.org\/10.1056\/nejmoa1917246.","journal-title":"N Engl J Med"},{"issue":"4","key":"1539_CR30","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/j.1600-0404.1982.tb03084.x","volume":"65","author":"U Patzold","year":"1982","unstructured":"Patzold U, Pocklington PR. Course of multiple sclerosis. First results of a prospective study carried out of 102 MS patients from 1976\u20131980. Acta Neurol Scand. 1982;65(4):248\u201366. https:\/\/doi.org\/10.1111\/j.1600-0404.1982.tb03084.x.","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"1539_CR31","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/j.1524-4733.2006.00144.x","volume":"10","author":"M Orme","year":"2007","unstructured":"Orme M, Kerrigan J, Tyas D, Russell N, Nixon R. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health. 2007;10(1):54\u201360. https:\/\/doi.org\/10.1111\/j.1524-4733.2006.00144.x.","journal-title":"Value Health"},{"key":"1539_CR32","unstructured":"Istituto Nazionale di Statistica (ISTAT). Tavole di mortalit\u00e0 2021 (I.Stat2022). 2022. http:\/\/demo.istat.it\/tvm2016\/index.php?lingua=ita. Accessed 15 Jan 2024."},{"issue":"8","key":"1539_CR33","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1007\/s00415-014-7370-3","volume":"261","author":"SS Jick","year":"2014","unstructured":"Jick SS, Li L, Falcone GJ, Vassilev ZP, Wallander MA. Mortality of patients with multiple sclerosis: a cohort study in UK primary care. J Neurol. 2014;261(8):1508\u201317. https:\/\/doi.org\/10.1007\/s00415-014-7370-3.","journal-title":"J Neurol"},{"key":"1539_CR34","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s40273-018-0683-9","volume":"36","author":"L Hernandez","year":"2018","unstructured":"Hernandez L, O\u2019Donnell M, Postma M. Modeling approaches in cost-effectiveness analysis of disease-modifying therapies for relapsing\u2013remitting multiple sclerosis: an updated systematic review and recommendations for future economic evaluations. Pharmacoeconomics. 2018;36:1223\u201352. https:\/\/doi.org\/10.1007\/s40273-018-0683-9.","journal-title":"Pharmacoeconomics"},{"issue":"18","key":"1539_CR35","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.2217\/cer-2020-0122","volume":"9","author":"IA Samjoo","year":"2020","unstructured":"Samjoo IA, Worthington E, Drudge C, Zhao M, Cameron C, H\u00e4ring DA, et al. Comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis. J Comp Eff Res. 2020;9(18):1255\u201374. https:\/\/doi.org\/10.2217\/cer-2020-0122.","journal-title":"J Comp Eff Res"},{"key":"1539_CR36","unstructured":"Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation (handbooks in health economic evaluation). Oxford University Press; 2026."},{"issue":"1","key":"1539_CR37","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7175\/fe.v20i1.1435","volume":"20","author":"PA Cortesi","year":"2019","unstructured":"Cortesi PA, Paolicelli D, Capobianco M, Cozzolino P, Mantovani LG. The value and sustainability of ocrelizumab in relapsing multiple sclerosis: a cost-effectiveness and budget impact analysis. Farmeconomia Health Econ Ther Pathways. 2019;20(1):61\u201372. https:\/\/doi.org\/10.7175\/fe.v20i1.1435.","journal-title":"Farmeconomia Health Econ Ther Pathways"},{"issue":"1","key":"1539_CR38","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1186\/s12913-019-4264-1","volume":"19","author":"G Furneri","year":"2019","unstructured":"Furneri G, Santoni L, Ricella C, Prosperini L. Cost-effectiveness analysis of escalating to natalizumab or switching among immunomodulators in relapsing\u2013remitting multiple sclerosis in Italy. BMC Health Serv Res. 2019;19(1):436. https:\/\/doi.org\/10.1186\/s12913-019-4264-1.","journal-title":"BMC Health Serv Res"},{"key":"1539_CR39","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/(SICI)1099-1050(199603)5:2<141::AID-HEC189>3.0.CO;2-N","volume":"5","author":"P Dolan","year":"1996","unstructured":"Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ. 1996;5:141\u201354.","journal-title":"Health Econ"},{"key":"1539_CR40","unstructured":"Agenzia Italiana del Farmaco. Lists of class A and class H medicinal products. Rome: AIFA. https:\/\/www.aifa.gov.it\/liste-farmaci-a-h. Accessed 15 Jan 2024."},{"key":"1539_CR41","unstructured":"Gazzetta Ufficiale della Repubblica Italiana (G.U.). 28 January 2013. Remunerazione delle prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. 2013. http:\/\/www.gazzettaufficiale.it\/eli\/gu\/2013\/01\/28\/23\/so\/8\/sg\/pdf. Accessed 20 Dec 2022."},{"key":"1539_CR42","unstructured":"Rivaluta ISTAT. https:\/\/rivaluta.istat.it\/. Accessed 27 July 2025."},{"issue":"6","key":"1539_CR43","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s41669-022-00363-1","volume":"6","author":"M Baharnoori","year":"2022","unstructured":"Baharnoori M, Bhan V, Clift F, Thomas K, Mouallif S, Adlard N, et al. Cost-effectiveness analysis of ofatumumab for the treatment of relapsing\u2013remitting multiple sclerosis in Canada. Pharmacoeconomics. 2022;6(6):859\u201370. https:\/\/doi.org\/10.1007\/s41669-022-00363-1.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"1539_CR44","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s41669-022-00381-z","volume":"7","author":"P Martins","year":"2023","unstructured":"Martins P, Vandewalle B, F\u00e9lix J, Capela CM, Cerqueira JJ, Salgado AV, et al. Cost-effectiveness analysis of ocrelizumab for the treatment of relapsing and primary progressive multiple sclerosis in Portugal. Pharmacoeconomics. 2023;7(2):229\u201341. https:\/\/doi.org\/10.1007\/s41669-022-00381-z.","journal-title":"Pharmacoeconomics"},{"issue":"12","key":"1539_CR45","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s40263-018-0566-9","volume":"32","author":"M Zimmermann","year":"2018","unstructured":"Zimmermann M, Brouwer E, Tice JA, Seidner M, Loos AM, Liu S, et al. Disease-modifying therapies for relapsing\u2013remitting and primary progressive multiple sclerosis: a cost-utility analysis. CNS Drugs. 2018;32(12):1145\u201357. https:\/\/doi.org\/10.1007\/s40263-018-0566-9.","journal-title":"CNS Drugs"},{"issue":"1","key":"1539_CR46","doi-asserted-by":"publisher","DOI":"10.1177\/20552173221085741","volume":"8","author":"D Koeditz","year":"2022","unstructured":"Koeditz D, Frensch J, Bierbaum M, Ness NH, Ettle B, Vudumula U, et al. Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: a cost-consequence analysis from a societal perspective in Germany. Mult Scler J. 2022;8(1):20552173221085741. https:\/\/doi.org\/10.1177\/20552173221085741.","journal-title":"Mult Scler J"},{"key":"1539_CR47","doi-asserted-by":"publisher","first-page":"S746","DOI":"10.1016\/j.jval.2019.09.1822","volume":"22","author":"M Gitlin","year":"2019","unstructured":"Gitlin M, Snyder S, Jhaveri M. PND52 payer and societal benefit of peginterferon beta-1a versus subcutaneous interferon beta-1a in patients with relapsing\u2013remitting multiple sclerosis in Italy. Value Health. 2019;22:S746. https:\/\/doi.org\/10.1016\/j.jval.2019.09.1822.","journal-title":"Value Health."},{"key":"1539_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102512","volume":"19","author":"H Inojosa","year":"2020","unstructured":"Inojosa H, Schriefer D, Ziemssen T. Clinical outcome measures in multiple sclerosis: a review. Autoimmun Rev. 2020;19:102512. https:\/\/doi.org\/10.1016\/j.autrev.2020.102512.","journal-title":"Autoimmun Rev"},{"key":"1539_CR49","unstructured":"National Institute for Health and Care Excellence. Ponesimod for treating relapsing\u2013remitting multiple sclerosis. Technology appraisal guidance TA767. London: NICE; 2022. https:\/\/www.nice.org.uk\/guidance\/TA767\/chapter\/1-Recommendations. Accessed 15 Jan 2024."},{"issue":"2","key":"1539_CR50","doi-asserted-by":"publisher","DOI":"10.1212\/cpj.0000000000200253","volume":"14","author":"EL Graham","year":"2024","unstructured":"Graham EL, Bove R, Costello K, et al. Practical considerations for managing pregnancy in patients with multiple sclerosis: dispelling the myths. Neurol Clin Pract. 2024;14(2):e200253. https:\/\/doi.org\/10.1212\/cpj.0000000000200253.","journal-title":"Neurol Clin Pract."},{"issue":"3","key":"1539_CR51","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1177\/1352458520952310","volume":"27","author":"A Riva","year":"2021","unstructured":"Riva A, Barcella V, Benatti SV, Capobianco M, Capra R, Cinque P, et al. Vaccinations in patients with multiple sclerosis: a Delphi consensus statement. Mult Scler. 2021;27(3):347\u201359. https:\/\/doi.org\/10.1177\/1352458520952310.","journal-title":"Mult Scler"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01539-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-025-01539-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-025-01539-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:34:54Z","timestamp":1765978494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-025-01539-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,18]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1539"],"URL":"https:\/\/doi.org\/10.1007\/s40273-025-01539-3","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,18]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"R Bergamaschi has received honoraria for speaking from Biogen, Merck Serono, Roche, Novartis, Celgene, Janssen, and Sanofi Genzyme; research grants from Biogen, Merck Serono, Roche, Novartis, and Sanofi Genzyme; and congress and travel\/accommodation expenses from Biogen, Merck Serono, Roche, Novartis, and Sanofi Genzyme. V Brescia Morra has received research grants from the Italian MS Society and Roche and honoraria from Bayer, Biogen, Merck, Mylan, Novartis, Roche, Sanofi-Genzyme, and Teva. L Prosperini has received consulting fees from Biogen, Merck, Novartis, and Roche; speaker honoraria from Biogen, Genzyme, Merck, Serono, Novartis, Roche, and Teva; travel grants from Biogen, Genzyme, Novartis, Roche, and Teva; and research grants from the Italian MS Society (Associazione Italiana Sclerosi Multipla) and Genzyme. PA Cortesi has received speaker honoraria from Novartis and Roche. C Fornari has no conflicts of interest. D Perini and L Santoni are employees of and may hold stock in Biogen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval is not required for simulation-based studies in the present study\u2019s jurisdiction.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Model input data are available within the paper, and simulation models are available upon request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data and code availability"}},{"value":"All authors contributed to the development of the economic model and approved its final version. All the authors revised and approved the conducted analyses and results. All authors are responsible for the revision of the manuscript. All authors read and approved the final version of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}